|
"huang d c l"的相关文件
顯示項目 11-20 / 23 (共3頁)
<< < 1 2 3 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Bogenrieder T; Twelves C; Cheng A.-L.; Huang D.C.-L; Strelkowa N; Goeldner R.-G; Schmid U; Fuertig R; Buschke S; Jove M; Anthoney A; Yen C.-J; de Bono J; Chia-Chi Lin; Chen L.-T; Corral J; Michalarea V; Rihawi K; Ong M; Lee J.-H; Hsu C.-H; Yang J.C.-H; Shiah H.-S |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Cheng A.-L.; Twelves C.; Bogenrieder T.; Huang D.C.-L.; Strelkowa N.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Shiah H.-S.; Yang J.C.-H.; CHIH-HUNG HSU; Lee J.-H.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Chih-Hung Hsu;Yang J.C.-H.;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L. |
| 國立成功大學 |
2020 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de, Bono J.;Lin, C.-C.;Chen, L.-T.;Corral, J.;Michalarea, V.;Rihawi, K.;Ong, M.;Lee, J.-H.;Hsu, C.-H.;Yang, J.C.-H.;Shiah, H.-S.;Yen, C.-J.;Anthoney, Anthoney A.;Jove, M.;Buschke, S.;Fuertig, R.;Schmid, U.;Goeldner, R.-G.;Strelkowa, N.;Huang, D.C.-L.;Bogenrieder, T.;Twelves, C.;Cheng, A.-L. |
| 國立成功大學 |
2018 |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen, C.-J.;Kim, T.-Y.;Feng, Y.-H.;Chao, Y.;Lin, D.-Y.;Ryoo, B.-Y.;Huang, D.C.-L.;Schnell, D.;Hocke, J.;Loemb�, A.-B.;Cheng, A.-L. |
顯示項目 11-20 / 23 (共3頁)
<< < 1 2 3 > >>
每頁顯示[10|25|50]項目
|
